Hikma Pharmaceuticals

Hikma is a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets it serves through the development, manufacturing and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (MENA) region, the United States and Europe. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index.

London, GB
Size (employees)
7,189 (est)
Hikma Pharmaceuticals was founded in 1978 and is headquartered in London, GB

Hikma Pharmaceuticals Office Locations

Hikma Pharmaceuticals has offices in London, Beirut, Cairo, Dubai and in 2 other locations
London, GB (HQ)
13 Hanover Square

Hikma Pharmaceuticals Data and Metrics

Hikma Pharmaceuticals Financial Metrics

Hikma Pharmaceuticals's revenue was reported to be £1.5 b in FY, 2016 which is a 51% increase from the previous period.

Revenue (FY, 2016)

1.5 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

762.1 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

122.1 m

Market capitalization (08-Sep-2017)

2.9 b

Closing share price (08-Sep-2017)


Cash (31-Dec-2016)

125.2 m
Hikma Pharmaceuticals's current market capitalization is £2.9 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


897.6 m1 b996.7 m1.5 b

Revenue growth, %


Cost of goods sold

395.2 m441.6 m430.5 m745.1 m

Gross profit

502.4 m589 m566.2 m762.1 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016


115.1 m199.3 m410.4 m125.2 m

Accounts Receivable

253.2 m265.8 m299 m586.6 m

Current Assets

589.9 m701.1 m941.3 m1.1 b


384.7 m440.2 m436 m924.4 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

221.6 m294.2 m253.3 m226.5 m

Cash From Financing Activities

(150.6 m)20.8 m53.3 m14.7 m

Income Taxes Paid

(53.9 m)(55.4 m)(44.3 m)(40.2 m)
Y, 2016

Financial Leverage

1.8 x
Show all financial metrics

Hikma Pharmaceuticals Market Value History

Traffic Overview of Hikma Pharmaceuticals

Hikma Pharmaceuticals Online and Social Media Presence

Hikma Pharmaceuticals News and Updates

Numis steals the crown of top City stockbroker from JP Morgan Cazenove

JP Morgan Cazenove has lots its top spot as the City's most popular stockbroker, as Numis Securities has crept ahead to take the largest number of stock market clients. With 189 clients to Numis's 195, this is the first time that JP Morgan Cazenove has ever lost its crown since Adviser Rankings b…

The FTSE 100 is calm in the aftermath of the London terror attack

LONDON — European markets are placid on Thursday morning as investors digest the terror attack perpetrated in London on Wednesday, and wait for a vote in the United States House of Representatives later in the day on the proposed overhaul of the Affordable Care Act, also kno…

FTSE 100 higher as bond sell-off pauses

The FTSE 100 rises in early trade, while the recent sell-off on the bond market pauses.

Hikma Pharmaceuticals has cut its full year sales guidance

FTSE 100 pharma firm Hikma has cut its full-year sales guidance for its US generics business to roughly $600m, against earlier analyst forecasts of $655m. Shares in the company have dipped in London, falling by some four per cent so far today.  The numbers Hikma now expect generics revenue …
Show more

Hikma Pharmaceuticals Company Life and Culture

You may also be interested in